61. O Connor CM, Hasselblad V, Mehta RH, et al. Triage after hospitali- zation with advanced heart failure: the ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effec- tiveness) risk model and discharge score. J Am Coll Cardiol 2010;55: 872 8. 62. Kociol RD, Horton JR, Fonarow GC, et al. Admission, discharge, or change in B-type natriuretic peptide and long-term outcomes: data from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) linked to Medicare claims. Circ Heart Fail 2011;4:628 36. 63. Okonko DO, Mandal AK, Missouris CG, et al. Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival. J Am Coll Cardiol 2011;58: 1241 51. 64. Costello-Boerrigter LC, Boerrigter G, Red eld MM, et al. Amino- terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. J Am Coll Cardiol 2006;47:345 53. 65. de Lemos JA, McGuire DK, Khera A, et al. Screening the population for left ventricular hypertrophy and left ventricular systolic dysfunction using natriuretic peptides: results from the Dallas Heart Study. Am Heart J 2009;157:746 53. 66. Goetze JP, Mogelvang R, Maage L, et al. Plasma pro-B-type natriuretic peptide in the general population: screening for left ventricular hyper- trophy and systolic dysfunction. Eur Heart J 2006;27:3004 10. 67. Ng LL, Loke IW, Davies JE, et al. Community screening for left ventricular systolic dysfunction using plasma and urinary natriuretic peptides. J Am Coll Cardiol 2005;45:1043 50. 68. Richards AM, Doughty R, Nicholls MG, et al. Plasma N-terminal pro- brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of bene t from carvedilol in chronic ischemic left ventricular dysfunction: Australia-New Zealand Heart Failure Group. J Am Coll Cardiol 2001;37:1781 7. 69. 